So, in the past the CEO said he was going to put FebriDx aside and focus on the services business to generate revenue. However, here we are again with another FDA application for FebriDx.
This should see the share price plummet once more during 2023. Oh, and again, no real update on what's happening with ViraDx. It was supposed to be in the US market months ago. Another false promise by Lumos Diagnostics. Are we surprised? No.
It looks like there will be no news until early 2024. See you then.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.6¢ |
Change
-0.003(6.58%) |
Mkt cap ! $17.32M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 3.6¢ | 3.4¢ | $136.5K | 3.888M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 310309 | 3.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.6¢ | 681362 | 2 |
View Market Depth
| Last trade - 14.52pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.6¢ |
Change
-0.003 ( 4.05 %) |
||||
| Open | High | Low | Volume | ||
| 3.6¢ | 3.6¢ | 3.4¢ | 1453857 | ||
| Last updated 15.22pm 24/05/2024 ? | |||||
| LDX (ASX) Chart |